Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A louver assembly for an exterior of a building, the assembly comprising: a louver carrier; a louver which is supportable by the louver carrier; and a locking mechanism, means or connector adapted to prevent or limit separation of the louver from the louver carrier The locking connector includes a deflectable first engagement element on one of the louver and the louver carrier, a second engagement element on the other of the louver and the louver carrier and which is engagable with the deflectable first engagement element, and a locking element adapted to prevent or limit movement of the deflectable first engagement element thereby preventing or inhibiting separation of the first and second engagement elements when interconnected.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: An exterior acoustic louvre comprises an internal structural mounting element which is adapted for mounting the louvre to an exterior mounting element, and which has a longitudinal sound-energy baffle extending in a front-to-rear-edge direction of the louvre and at least one lateral sound-energy baffle extending in a top-to-bottom-surface direction of the louvre. At least one sound-energy absorption element overlies at least a majority of the upper and lower surfaces of the longitudinal sound-energy baffle. A sound-attenuating baffle cavity is provided between the upper and lower surfaces of the longitudinal sound-energy baffle, the sound-attenuating baffle cavity extending across at least a majority of a lateral extent of the longitudinal sound-energy baffle. An exterior solar-shading system for a building, comprising a plurality of such exterior acoustic louvres is also provided.

Abstract: A solar-shading assembly for fastening to a support mullion, comprises an elongate louver member having longitudinal front and rear edges, an elongate cap element for extending along and covering the rear edge, a bracket which is connectable to the support mullion, and a fastening device for connecting the bracket to the rear edge of the louver member. The in use fastening device is coverable by the cap element so as to hide the fastening device from view. Preferably, at least part of the bracket is also coverable by the cap element so as to hide the said part of the bracket from view.

Abstract: An exterior acoustic louvre comprises a louvre body which defines major upper and lower surfaces and minor side surfaces. The louvre body includes a support element, a sound-energy absorption element supported by the support element, and a flexible plastics watertight element which watertightly encases the sound-energy absorption element. The louvre body is arranged so that the watertightly encased sound-energy absorption element can receive sound energy in the directions of both the upper and lower major surfaces of the louvre body.

Abstract: There is provided a method of attaching bracket apparatus to a curtain wall mullion having a fastening channel for receiving screw-threaded fasteners for a bracket element having upper and lower attachment ports. The method comprises the steps of: a) positioning the bracket element on the fastening channel so that a longitudinal opening of the channel is blocked along the longitudinal extent of the bracket element, and providing upper and lower blocking elements within the fastening channel so that the upper and lower attachment ports are in between the upper and lower blocking elements; and b) forcing an adhesive into one of the said upper and lower attachment ports until it appears in the other of the upper and lower attachment ports. There is also provided curtain walling bracket apparatus for use in such a method, and curtain wall mullion apparatus wherein said curtain walling bracket apparatus is attached to a curtain wall mullion using said method.

Abstract: Exterior solar shading comprises at least one elongate rigid light-transmissible louver. The louver has an infra-red filter element which prevents or limits the transmission of infra-red energy, and a light redirection element which reflect visible light passing through the louver. The light redirecting element is integrally formed in a major surface of an outer louver element of the louver. Preferably, the light redirecting element is a plurality of formations such as recesses, for example, grooves, or projections, which may preferably have at least one mirrored surface.

Abstract: An adapter (22) for attaching a solar-shading bracket (30) to a curtain walling mullion (10), comprises a body element (24) for location on the curtain walling mullion (10) and adapted to support the solar-shading bracket (30), mullion attaching means (26) for attaching the body element (24) to the curtain walling mullion (10), and bracket attaching means (28) for attaching the solar-shading bracket (30) to the adapter (22). A method and a apparatus having an energy break device are also provided.